- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
On 11 October, Pharmac, New Zealand’s Crown entity responsible for medicines and pharmaceutical products, has announced a deal with Merck Sharp & Dohme to purchase 60,000 courses of molnupiravir, the antiviral oral drug used to treat mild to moderate COVID-19 symptoms. The drug is subject to approval for use in the country by Medsafe. The government is continuing to promote vaccination as the first line of defence against COVID-19.
Pandemic Information Webinars
(Available to Pandemic Subscribers only)
Register for upcoming events
View/Download previous webinars
Additional data provided by
English
Japanese
